Related Experiment Video
Updated: May 10, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Directed phenotype switching as an effective antimelanoma strategy
Magalí Sáez-Ayala1, María F Montenegro, Luis Sánchez-Del-Campo
1Department of Biochemistry and Molecular Biology A, School of Biology, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, 30100 Murcia, Spain.
Cancer Cell
|June 25, 2013
Summary
This study shows that combining methotrexate (MTX) with a specific prodrug sensitizes melanoma cells to therapy by inducing differentiation. This targeted approach offers effective, tissue-restricted melanoma treatment regardless of genetic mutations.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Therapeutic resistance in melanoma and other cancers is often driven by genetic and phenotypic heterogeneity.
- Developing strategies to overcome this resistance is crucial for effective cancer treatment.
Purpose of the Study:
- To investigate directed phenotype switching in melanoma to sensitize cancer cells to lineage-specific therapy.
- To evaluate a novel combination therapy for melanoma treatment.
Main Methods:
- Utilized methotrexate (MTX) to induce microphthalmia-associated transcription factor (MITF) expression, promoting differentiation and inhibiting invasiveness.
- Developed a tyrosinase-processed antifolate prodrug (TMECG) that inhibits dihydrofolate reductase (DHFR).
- Assessed the efficacy of the MTX and TMECG combination in vitro and in vivo, analyzing DNA damage and apoptosis induction.
Main Results:
- Methotrexate (MTX) treatment increased microphthalmia-associated transcription factor (MITF) expression, leading to differentiation and increased Tyrosinase gene expression.
- MTX sensitized melanoma cells to the tyrosinase-processed prodrug TMECG, which potently inhibits DHFR.
- The combination therapy resulted in thymidine pool depletion, DNA double-strand breaks, and robust E2F1-mediated apoptosis.
- This combination therapy demonstrated effective and tissue-restricted antimelanoma activity in both cell culture and animal models, irrespective of BRAF, MEK, or p53 mutation status.
Conclusions:
- Directed phenotype switching using MTX can sensitize melanoma cells to targeted therapies.
- The combination of MTX and TMECG represents a promising strategy for effective and selective melanoma treatment.
- This approach holds potential for overcoming therapeutic resistance in melanoma, regardless of common genetic alterations.
